SCHEMBL13615206

SCHEMBL13615206

CC(C)(C)c1ccc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2)cc1F

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 4/20 0.60
FFAR1 O14842 2/20 0.60
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
CDK1 P06493 1/20 0.51
CCNB1 P14635 1/20 0.51
CCNA2 P20248 1/20 0.51
CDK2 P24941 1/20 0.51
CDK7 P50613 1/20 0.51
CCNH P51946 1/20 0.51
CCNA1 P78396 1/20 0.51
RORA P35398 1/20 0.51
BRD4 O60885 1/20 0.50
MAPT P10636 2/20 0.49
UQCRB P14927 2/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13615091 0.86 FFAR4 (0.60) FFAR4FFAR1MEN1KMT2AALOX15
SCHEMBL13615168 0.86 HSD17B2 (0.61) FFAR4FFAR1MEN1KMT2AMAPK1
SCHEMBL13615120 0.85 CES1 (0.57) FFAR4FFAR1MEN1KMT2AMAPK1
SCHEMBL13615156 0.83 FFAR4 (0.60) FFAR4MEN1KMT2AMAPK1MAPT
SCHEMBL13615251 0.82 CDK1 (0.52) FFAR4FFAR1CDK1CCNB1CCNA2
SCHEMBL13629417 0.81 KMT2A (0.52) FFAR4FFAR1MEN1KMT2AALOX15
SCHEMBL13615171 0.80 MEN1 (0.48) FFAR4FFAR1MEN1KMT2AMAPT
SCHEMBL14601685 0.79 MEN1 (0.65) MEN1KMT2AALOX15MAPK1RORA
SCHEMBL13615174 0.78 SLC22A12 (0.78) BRD4CYP3A4SLC22A12
SCHEMBL15603554 0.78 FFAR1 (0.72) FFAR4FFAR1MEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK FFAR4 3554/4885FFAR1 3033/4885MEN1 1723/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK FFAR4 3913/4885FFAR1 3586/4885MEN1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.